Join Daxor Corporation's CEO at the Maxim Healthcare Virtual Summit
Daxor Corporation (Nasdaq: DXR), a frontrunner in blood volume measurement technology, is gearing up for an exciting opportunity to engage with investors and industry leaders. CEO and President Michael Feldschuh will take part in an enlightening fireside chat during the forthcoming 2024 Maxim Healthcare Virtual Summit. This event promises to be a key moment for Daxor as it showcases its innovative contributions to healthcare.
Event Highlights and Participant Information
Scheduled between October 15 and 17, the summit will provide an invaluable platform for discussing advancements in medical technology, specifically blood volume measurement. In this unique setting, Mr. Feldschuh will converse with Anthony Vendetti, a seasoned Director of Research and Senior Healthcare Analyst at Maxim. Their dialogue will revolve around the critical role of accurate blood volume assessments in improving patient outcomes and hospital efficiency.
Details of the Fireside Chat
The fireside chat is set to commence on Tuesday, October 15, at 10:00 AM ET, where stakeholders will have a chance to delve into Daxor's operational strategies. Mr. Feldschuh is also open to one-on-one meetings with registered investors during the summit, ensuring personalized interaction and discussions around Daxor's innovative technology.
Expanding Investor Engagement
Investors interested in Daxor's pioneering technology in fluid management are encouraged to reach out to Bret Shapiro at CORE IR for more details. Potential attendees can contact him at 1-516-222-2560 or through email.
About Daxor Corporation
Daxor Corporation has cemented its position as the global leader in blood volume measurement technology. The company has developed the BVA-100™ (Blood Volume Analyzer), a groundbreaking diagnostic tool cleared by the FDA. This device accurately quantifies blood volume status against patient-specific benchmarks. With over 65,000 tests conducted in leading hospital centers across the country, Daxor has made significant contributions to reducing mortality and readmissions in heart failure cases.
Innovation and Future Directions
Daxor is committed to advancing its mission: improving healthcare through effective fluid management and blood volume analysis. This focus has led to ongoing trials aimed at enhancing heart failure treatment, further backed by the NIH. Additionally, Daxor is collaborating with the U.S. Department of Defense to develop analyzers that will enhance combat casualty care. The company's vision is clear: to achieve optimal blood volume management for all patients, ultimately improving healthcare outcomes nationwide.
Path Ahead for Daxor
By actively participating in events such as the Maxim Healthcare Virtual Summit, Daxor Corporation is not only enhancing its visibility but also strengthening its relationships with investors. This interaction is crucial for sharing insights, discussing ongoing trials, and exploring future innovations that could transform patient care.
Frequently Asked Questions
What is the purpose of the fireside chat at the Maxim Healthcare Virtual Summit?
The fireside chat aims to discuss Daxor's blood volume measurement technologies and their role in improving patient care with investors and industry experts.
Who will be participating in the fireside chat?
CEO Michael Feldschuh will engage in conversation with Maxim's Director of Research, Anthony Vendetti.
How can investors connect with Daxor Corporation during the summit?
Investors can schedule one-on-one meetings with Mr. Feldschuh by registering for the summit and reaching out to Bret Shapiro at CORE IR.
What are some notable achievements of Daxor Corporation?
Daxor has performed over 65,000 blood volume tests, significantly reducing readmission rates in heart failure and enhancing surgical outcomes.
What innovative technologies is Daxor developing currently?
Daxor is focusing on trials for heart failure treatment and developing analyzers for improving casualty care, backed by collaborations with the Department of Defense.
